GA GENERIC ASSAYS GMBH has a total of 21 patent applications. It decreased the IP activity by 85.0%. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets measurement, chemical engineering and pharmaceuticals are ASS CAPE COD INC, MEDICAL TECHNOLOGY CORP and HAZEN STANLEY L.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | United States | 3 | |
#4 | Australia | 2 | |
#5 | Canada | 2 | |
#6 | China | 2 | |
#7 | Germany | 1 | |
#8 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Measurement | |
#2 | Chemical engineering | |
#3 | Pharmaceuticals | |
#4 | Biotechnology | |
#5 | Computer technology |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Peptides | |
#3 | Chemical or physical processes | |
#4 | Separation | |
#5 | Medical preparations | |
#6 | Therapeutic chemical compounds | |
#7 | Bioinformatics | |
#8 | Electric digital data processing |
# | Name | Total Patents |
---|---|---|
#1 | Roggenbuck Dirk | 20 |
#2 | Schierack Peter | 1 |
#3 | Deutschmann Claudia | 1 |
#4 | Roggenbuck Dirk Dr | 1 |
Publication | Filing date | Title |
---|---|---|
US2020209258A1 | Gp2 isoforms and their use in autoantibody capture | |
WO2019015814A1 | Chitinase-3-like protein 1 (chi3l1) as an autoantigen in autoimmune disorders of the digestive system | |
EP3299818A1 | Method for the diagnosis of acute pancreatitis (ap) by detection of glycoprotein 2 isoform alpha (gp2a) | |
WO2016005354A1 | Autoantibody profiling in aps | |
EP2913675A2 | GP2 isoforms and their use in autoantibody capture | |
EP2126582A2 | Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis | |
EP1950222A1 | Method for detecting antibodies in body fluids via an immune reaction with glycoprotein 2 (GP2) from zymogen granula of the pancreas for a differential diagnosis of inflammatory bowel diseases and chronic pancreatitis | |
DE102007004909A1 | Use of pancreatic zymogen granule polypeptide GP2 as a medicament, especially for treating autoimmune diseases by plasmapheresis |